Most Read Articles
Tristan Manalac, 12 Feb 2020
Incorporating genotyping of human adenovirus (HAdV) infections in clinical practice may inform risk stratification and treatment decisions, according to a new Singapore study.
Tristan Manalac, 25 Oct 2019
Old age and lower white cell counts are significant risk factors for poor platelet recovery among dengue patients with thrombocytopaenia, according to a recent Singapore study.
14 Feb 2020
A 10-day or 14-day sequential therapy strategy is more cost-effective than a conventional triple therapy in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.
Tristan Manalac, 04 Sep 2019
A booster injection of CYD-TDV (Dengvaxia) can generally restore antidengue antibody titres 5 years after a three-dose schedule, according to a new Singapore study.

Original New Drug Application Approvals by US FDA (01- 15 February 2019)

15 Feb 2019
New drug applications approved by US FDA as of 01- 15 February 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

JEUVEAU
  • Active Ingredient(s): PrabotulinumtoxinA-xvfs
  • Strength: 100 units
  • Dosage Form(s) / Route(s): Injectable; Injection
  • Company: Evolus Inc.
  • Approval Date: 01 Feb 2019
  • Submission Classification: Not Available
  • Indication(s): Indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients
  • Approved Label: 01 Feb 2019 (PDF)

CABLIVI
  • Active Ingredient(s): Caplacizumab-yhdp
  • Strength: 11 mg/vial
  • Dosage Form(s) / Route(s): Injectable; Injection
  • Company: Ablynx NV
  • Approval Date: 06 Feb 2019
  • Submission Classification: Not Available
  • Indication(s): Indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP),in combination with plasma exchange and immunosuppressive therapy
  • Approved Label: 06 Feb 2019 (PDF)

EGATEN
  • Active Ingredient(s): Triclabendazole
  • Strength: 250 mg
  • Dosage Form(s) / Route(s): Tablet; Oral
  • Company: Novartis Pharms Corp
  • Approval Date: 13 Feb 2019
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of fascioliasis in patients 6 years of age and older.
  • Approved Label: 13 Feb 2019 (PDF)

VANCOMYCIN
  • Active Ingredient(s): Vancomycin
  • Strength: 500mg/100mL; 1g/200mL; 1.5g/300mL
  • Dosage Form(s) / Route(s): Injectable; Injection
  • Company: Xellia Pharms ApS
  • Approval Date: 15 Feb 2019
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated in adult and pediatric patients (1 month and older) for the treatment of:  septicemia, infective endocarditis, skin and skin structure infections, bone infections, lower respiratory tract infections.
  • Approved Label: 15 Feb 2019 (PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 12 Feb 2020
Incorporating genotyping of human adenovirus (HAdV) infections in clinical practice may inform risk stratification and treatment decisions, according to a new Singapore study.
Tristan Manalac, 25 Oct 2019
Old age and lower white cell counts are significant risk factors for poor platelet recovery among dengue patients with thrombocytopaenia, according to a recent Singapore study.
14 Feb 2020
A 10-day or 14-day sequential therapy strategy is more cost-effective than a conventional triple therapy in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.
Tristan Manalac, 04 Sep 2019
A booster injection of CYD-TDV (Dengvaxia) can generally restore antidengue antibody titres 5 years after a three-dose schedule, according to a new Singapore study.